EC closes antitrust case against AstraZeneca and Nycomed
This article was originally published in Scrip
The European Commission has ended its antitrust investigation into AstraZeneca and Nycomed, confirming that it could not find any evidence of wrongdoing. The commission was investigating whether the companies had taken actions to delay the market entry of generic medicines, thereby harming healthcare providers and consumers.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.